Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
View Patent ↗The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
1. A method for treating a patient having a cancer associated with FN14 expression, comprising administering to the patient a composition comprising a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to human FN14, wherein the antibody or fragment thereof comprises:
(a) a heavy chain variable region comprising the VHCDR1 amino acid sequence set forth in SEQ ID NO:79, the VHCDR2 amino acid sequence set forth in SEQ ID NO:92 wherein Xaa at position 4 is Asp or Tyr, and the VHCDR3 amino acid sequence set forth in SEQ ID NO:93, wherein Xaa at position 2 is Ala or Gly, Xaa at position 4 is Ser or Thr, and Xaa at position 5 is Ser or Gly; and
(b) a light chain variable region comprising the VLCDR1 amino acid sequence set forth in SEQ ID NO:86, the VLCDR2 amino acid sequence set forth in SEQ ID NO:39 and the VLCDR3 amino acid sequence set forth in SEQ ID NO:94, wherein Xaa at position 3 is Ala or Ile;
and wherein the antibody or antigen-binding fragment thereof is at least one of (i) conjugated to a therapeutic agent, or (ii) wherein the antibody comprises an IgG Fe domain which is modified such that the antibody has enhanced ADCC activity as compared to the antibody having the unmodified IgG Fc domain;
thereby treating the cancer associated with FN14 expression.
2. The method of claim 1 , wherein the VHCDR3 of the heavy chain variable region comprises SEQ ID NO:84.
3. The method of claim 1 , wherein the VHCDR3 of the heavy chain variable region comprises SEQ ID NO:83.
4. The method of claim 1 , wherein the VHCDR3 of the heavy chain variable region comprises SEQ ID NO:76.
5. The method of claim 1 , wherein the heavy chain variable region comprises any one of the amino acid sequences set forth in SEQ ID NOs: 65, 66 or 67.
6. The method of claim 1 , wherein the light chain variable region comprises any one of the amino acid sequences set forth in SEQ ID NOs: 23, 24 or 25.
7. The method of claim 1 , wherein the antibody is selected from the group consisting of a single chain antibody, a ScFv, a univalent antibody lacking a hinge region, a minibody, a Fab, a Fab′ fragment, a F(ab′) 2 fragment and a whole antibody.
8. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is conjugated to a therapeutic agent.
9. The method of claim 1 , wherein the therapeutic agent is a drug or a toxin.
10. The method of claim 1 , wherein the antibody comprises a human IgG Fc domain.
11. The method of claim 10 , wherein the human IgG Fc domain is modified such that the antibody has enhanced ADCC activity as compared to the antibody having the unmodified human IgG Fe domain.
12. The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, salivary carcinoma, breast cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, colorectal cancer, non-small cell lung cancer, renal cancer, head and neck cancer, bladder cancer, uterine cancer, stomach cancer, esophageal cancer, pancreatic cancer, and glioblastoma multiforme.
13. A method for preventing or reducing the likelihood of occurrence of metastasis of a cancer associated with FN14 expression, comprising administering to a patient suffering with a cancer associated with FN14 expression a composition comprising a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to human FN14, wherein the antibody or fragment thereof comprises:
(a) a heavy chain variable region comprising the VHCDR1 amino acid sequence set forth in SEQ ID NO:79, the VHCDR2 amino acid sequence set forth in SEQ ID NO:92 wherein Xaa at position 4 is Asp or Tyr, and the VHCDR3 amino acid sequence set forth in SEQ ID NO:93, wherein Xaa at position 2 is Ala or Gly, Xaa at position 4 is Ser or Thr, and Xaa at position 5 is Ser or Gly; and
(b) a light chain variable region comprising the VLCDR1 amino acid sequence set forth in SEQ ID NO:86, the VLCDR2 amino acid sequence set forth in SEQ ID NO:39 and the VLCDR3 amino acid sequence set forth in SEQ ID NO:94, wherein Xaa at position 3 is Ala or Ile;
and wherein the antibody or antigen-binding fragment thereof is at least one of (i) conjugated to a therapeutic agent, or (ii) wherein the antibody comprises an IgG Fc domain which is modified such that the antibody has enhanced ADCC activity as compared to the antibody having the unmodified IgG Fe domain;
thereby preventing or reducing the likelihood of occurrence of a metastasis of the cancer associated with FN14 expression.
14. The method of claim 13 , wherein the cancer is selected from the group consisting of melanoma, salivary carcinoma, breast cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, colorectal cancer, non-small cell lung cancer, renal cancer, head and neck cancer, bladder cancer, uterine cancer, stomach cancer, esophageal cancer, pancreatic cancer, and glioblastoma multiforme.
15. The method of claim 13 , wherein the antibody or antigen-binding fragment thereof is conjugated to a therapeutic agent.
16. The method of claim 15 , wherein the therapeutic agent is a drug or a toxin.
17. The method of claim 13 , wherein the antibody comprises a human IgG Fc domain.
18. The method of claim 17 , wherein the human IgG Fc domain is modified such that the antibody has enhanced ADCC activity as compared to the antibody having the unmodified human IgG Fc domain.
19. The method of claim 1 wherein the antibody or antigen binding fragment thereof is humanized.
20. The method of claim 13 wherein the antibody or antigen binding fragment thereof is humanized.